RS59098B1 - Nova fuzionisana piridin jedinjenja kao inhibitori kazein kinaze - Google Patents

Nova fuzionisana piridin jedinjenja kao inhibitori kazein kinaze

Info

Publication number
RS59098B1
RS59098B1 RS20191036A RSP20191036A RS59098B1 RS 59098 B1 RS59098 B1 RS 59098B1 RS 20191036 A RS20191036 A RS 20191036A RS P20191036 A RSP20191036 A RS P20191036A RS 59098 B1 RS59098 B1 RS 59098B1
Authority
RS
Serbia
Prior art keywords
kinase inhibitors
casein kinase
pyridine compounds
fused pyridine
novel fused
Prior art date
Application number
RS20191036A
Other languages
English (en)
Inventor
Todd W Butler
Ramalakshmi Y Chandrasekaran
Scot R Mente
Chakrapani Subramanyam
Travis T Wager
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of RS59098B1 publication Critical patent/RS59098B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
RS20191036A 2010-12-20 2011-12-06 Nova fuzionisana piridin jedinjenja kao inhibitori kazein kinaze RS59098B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425213P 2010-12-20 2010-12-20
EP17151228.8A EP3181133B1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
RS59098B1 true RS59098B1 (sr) 2019-09-30

Family

ID=45446116

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20170387A RS55897B1 (sr) 2010-12-20 2011-12-06 Nova jedinjenja spojenih piridina kao inhibitori kazein kinaze
RS20191036A RS59098B1 (sr) 2010-12-20 2011-12-06 Nova fuzionisana piridin jedinjenja kao inhibitori kazein kinaze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20170387A RS55897B1 (sr) 2010-12-20 2011-12-06 Nova jedinjenja spojenih piridina kao inhibitori kazein kinaze

Country Status (24)

Country Link
US (1) US8536164B2 (sr)
EP (2) EP2654750B1 (sr)
JP (2) JP5684923B2 (sr)
KR (1) KR101590236B1 (sr)
CN (1) CN103260622B (sr)
AR (1) AR084412A1 (sr)
AU (1) AU2011346733C1 (sr)
CA (1) CA2819961C (sr)
CY (2) CY1118772T1 (sr)
DK (2) DK3181133T3 (sr)
ES (2) ES2623387T3 (sr)
HK (1) HK1188145A1 (sr)
HR (2) HRP20170484T1 (sr)
HU (2) HUE032405T2 (sr)
IL (1) IL226948A (sr)
LT (2) LT2654750T (sr)
MX (1) MX338551B (sr)
PL (2) PL2654750T3 (sr)
PT (2) PT2654750T (sr)
RS (2) RS55897B1 (sr)
SG (1) SG190802A1 (sr)
SI (2) SI2654750T1 (sr)
WO (1) WO2012085721A1 (sr)
ZA (1) ZA201303453B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051858A1 (en) * 2009-10-28 2011-05-05 Pfizer Inc. Imidazole derivatives as casein kinase inhibitors
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
CN104837844B (zh) * 2012-12-21 2017-08-29 百时美施贵宝公司 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
WO2015163446A1 (ja) * 2014-04-25 2015-10-29 協和発酵キリン株式会社 イミダゾール化合物の製造方法
JP2017222576A (ja) * 2014-10-31 2017-12-21 石原産業株式会社 有害生物防除剤
CN107365315A (zh) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
CN115335057A (zh) * 2020-03-27 2022-11-11 北京原基华毅生物科技有限公司 抑制酪蛋白激酶的方法
CN115298183A (zh) * 2020-03-27 2022-11-04 北京原基华毅生物科技有限公司 作为酪蛋白激酶抑制剂的化合物
CN111808102B (zh) * 2020-08-03 2021-12-31 南通大学 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法
JP2023541463A (ja) * 2020-09-17 2023-10-02 ヤンセン ファーマシューティカ エヌ.ベー. カゼインキナーゼ1デルタモジュレーター
JP2023541465A (ja) * 2020-09-17 2023-10-02 ヤンセン ファーマシューティカ エヌ.ベー. カゼインキナーゼ1デルタモジュレーター
CN116888126A (zh) * 2020-12-15 2023-10-13 北京原基华毅生物科技有限公司 一种酪蛋白激酶抑制剂的化合物
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
WO2023241552A1 (en) * 2022-06-14 2023-12-21 Gritscience Biopharmaceuticals Co., Ltd Salt and/or crystal form for compounds as casein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
NZ501112A (en) * 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
JP2003518123A (ja) * 1999-12-21 2003-06-03 スージェン・インコーポレーテッド 4−置換7−アザ−インドリン−2−オンおよびその蛋白質キナーゼ阻害剤としての使用
CN101242839B (zh) 2005-06-22 2012-11-07 凯莫森特里克斯股份有限公司 氮杂吲唑化合物及其制药用途
WO2007140213A1 (en) 2006-05-26 2007-12-06 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011051858A1 (en) * 2009-10-28 2011-05-05 Pfizer Inc. Imidazole derivatives as casein kinase inhibitors

Also Published As

Publication number Publication date
HK1188145A1 (en) 2014-04-25
ES2744099T3 (es) 2020-02-21
EP2654750A1 (en) 2013-10-30
MX2013005833A (es) 2013-07-05
KR20130121126A (ko) 2013-11-05
WO2012085721A1 (en) 2012-06-28
CY1118772T1 (el) 2017-07-12
IL226948A (en) 2017-04-30
US20120157440A1 (en) 2012-06-21
JP5684923B2 (ja) 2015-03-18
SI2654750T1 (sl) 2017-04-26
EP3181133B1 (en) 2019-07-24
KR101590236B1 (ko) 2016-01-29
DK3181133T3 (da) 2019-08-26
LT3181133T (lt) 2019-09-25
AU2011346733C1 (en) 2015-12-24
EP2654750B1 (en) 2017-03-08
HRP20191469T1 (hr) 2019-11-29
HUE032405T2 (en) 2017-09-28
PT2654750T (pt) 2017-05-04
HRP20170484T1 (hr) 2017-06-02
DK2654750T3 (en) 2017-05-01
MX338551B (es) 2016-04-20
AR084412A1 (es) 2013-05-15
CA2819961A1 (en) 2012-06-28
JP2015107992A (ja) 2015-06-11
CN103260622A (zh) 2013-08-21
ES2623387T3 (es) 2017-07-11
CA2819961C (en) 2015-08-18
LT2654750T (lt) 2017-05-10
US8536164B2 (en) 2013-09-17
CY1122062T1 (el) 2020-11-25
PT3181133T (pt) 2019-09-16
AU2011346733B2 (en) 2015-08-13
JP2014503544A (ja) 2014-02-13
CN103260622B (zh) 2015-05-13
EP3181133A1 (en) 2017-06-21
RS55897B1 (sr) 2017-08-31
ZA201303453B (en) 2014-07-30
HUE047089T2 (hu) 2020-04-28
SI3181133T1 (sl) 2019-10-30
AU2011346733A1 (en) 2013-07-18
SG190802A1 (en) 2013-07-31
JP5876596B2 (ja) 2016-03-02
PL2654750T3 (pl) 2017-07-31
PL3181133T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
HK1188145A1 (en) Novel fused pyridine compounds as casein kinase inhibitors
HK1192247A1 (zh) 作為激酶抑制劑的雜環化合物
HK1199203A1 (en) Kinase inhibitor polymorphs
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
PT2531501E (pt) Inibidores da cinase de regulação do sinal de apoptose 1
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
ZA201208489B (en) Fused bicyclic kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1201271A1 (en) Kinase inhibitor polymorphs
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
ZA201401416B (en) Novel rock kinase inhibitors
HK1209316A1 (en) Substituted picolinamide kinase inhibitors
GB201109162D0 (en) Casein kinase 1Delta (CK1Delta) inhibitors
GB201021161D0 (en) Casein kinase 1delta (CK1Delta) inhibitors
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101821D0 (en) Novel heterocyclic compounds 1
GB201101822D0 (en) Novel heterocyclic compounds 2
GB201101823D0 (en) Novel heterocyclic compounds 4